Juan Jose Gonzalez, who was the CEO of medtech firm Ambu until very recently, has lost just over DKK 16m (USD 2.3m) before taxes on his share purchases.
”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.
Britt Meelby Jensen, who was appointed the new chief executive of Ambu yesterday, is the obvious candidate to rebuild trust in the medtech firm after years of downgrades, say analysts.
After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.
Thursday’s CEO change had been in the works for a while, says Ambu’s board chair Jørgen Jensen.
Juan Jose Gonzalez steps down as chief executive of Ambu on May 20, as Britt Meelby Jensen assumes charge. (Updated)
As a direct consequence of new EU regulation for the medtech industry, firms have started to launch in the US before Europe, which wasn’t always the case previously, says the chief executive of industry association Medtech Europe.
Danish medtech firm Coloplast has been keeping a DKK 500m (USD 71m) secret since it acquired Atos Medical.
The medtech firm has announced that it is establishing a program to sell senior unsecured notes for up to EUR 3.5bn, aiming to finance the acquisition of Atos Medical.
After redesigning an ostomy product based on brand new technology, Coloplast has now achieved the desired clinical results. However, the company does not expect to be able to launch the platform within the previously announced period.
Juan Jose Gonzalez has been the chief executive of Ambu since 2019, and since then, the medtech firm has downgraded its guidance seven times. Going forward, expectations will fall on the conservative side, he says.
Around 70 employees in Russia will continue working, as the medtech firm keeps operations running in the country – out of concern for people with intimate health needs, says CEO Kristian Villumsen.
Atos Medical, which was officially acquired by Coloplast in January, has been allowed to keep its name. Still, the medtech firm’s parent company will have a say in future strategy matters, according to CFO Anders Lonning-Skovgaard.
The Danish medtech firm has announced in a stock exchange notification that it is lowering its expectations for the year due to a number of current and upcoming challenges.
The medtech firm has announced a smaller adjustment to its full-year outlook for organic growth, going to 6–7% from 7%, due to the pandemic’s impact in China.
Medtech firm Ambu’s Ascope 5 Broncho device has been granted the CE mark by European authorities.
US-based Boston Scientific has publicized its first quarter report, which surpassed analysts’ revenue expectations.
The upcoming wave of financial reports may bring a number of downward adjustments in its wake, assesses Niels Granholm-Leth, head of equity analysis at Carnegie. This applies to Ambu and GN, among others.
FRENCH ELECTION: An aging population and a gradual shift towards the idea of treating people in their own homes has led to intense work for Danish medtech firm Qufora, which is aiming for a revenue of DKK 20-40m (USD 2.9–5.9m) in the nearest future. ”France is our most underexploited close market,” says Qufora’s CEO.
FRENCH ELECTION: France’s aging population and greater focus on healthcare in people’s own homes could lead to Danish health technology exports of over USD 1bn. ”It’s a very exciting agenda,” says Denmark’s ambassador to France.
Exports of medical devices from the EU and US to Russia are starting again after having come to a halt due to Russia’s invasion of Ukraine.
Following approvals in the EU and Japan for a single-use gastroscope and a display unit, Ambu has announced the launches of both products on these markets.
Ambu will address over one million more procedures within its ear, nose and throat segment by adding a new capability to its single-use endoscope.
Advantageous market conditions for the Danish medtech firm, which has established a new division in its organization, will manifest as positive growth in the second quarter, says a Sydbank analyst.
The British medtech firm and Coloplast rival, Smith & Nephew, goes up on the London stock exchange after publicizing its Q1 figures.
Consultant Manager 
Director Global Engineering 
SAP System Specialist (Product Supply) – Business Application Services 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Project Manager & Scrum Master 
Strategic Procurement Manager, Direct Spend (Category Manager) 
Client Talent Acquisition Specialist 
Senior QA Specialist 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Director for innovative pre-clinical testing unit 
Senior Project Manager (GMP - Life Science) 
Nordic Medical Affairs Manager Innovation Project Manager, Display Unit Industrial Designer- Design Engineer 
Clinical Trial Manager Chemist for Incoming Materials in QC Department 
Analytical Coordinator for Analytical Development 
IRT Manager, Clinical Drug Supply Clinical Project Manager Senior IT Network Engineer 2 Sales Representatives and Product Specialists Clinical Trial Administrator 
Production Director 
Senior Chemical Safety Advisor 
